Processing

Please wait...

Settings

Settings

1. WO2017207432 - NOVEL COMPOUNDS

Publication Number WO/2017/207432
Publication Date 07.12.2017
International Application No. PCT/EP2017/062756
International Filing Date 26.05.2017
IPC
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14
containing three or more hetero rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
413
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
14
containing three or more hetero rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
403
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
02
containing two hetero rings
04
directly linked by a ring-member-to-ring- member bond
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
403
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
14
containing three or more hetero rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
415
1,2-Diazoles
4152
having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
415
1,2-Diazoles
4155
not condensed and containing further heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11
Drugs for disorders of the respiratory system
C07D 401/14 (2006.01)
C07D 413/14 (2006.01)
C07D 403/04 (2006.01)
C07D 403/14 (2006.01)
A61K 31/4152 (2006.01)
A61K 31/4155 (2006.01)
CPC
A61K 31/277
A61K 31/4152
C07D 231/44
C07D 249/08
C07D 401/04
C07D 401/14
Applicants
  • CHIESI FARMACEUTICI S.P.A. [IT/IT]; Via Palermo, 26/A 43122 PARMA, IT
Inventors
  • SUTTON, Jonathan Mark; IT
  • HEALD, Robert Andrew; IT
  • JENNINGS, Andrew Stephen Robert; IT
  • CAPALDI, Carmelida; IT
  • ARMANI, Elisabetta; IT
Agents
  • MINOJA, Fabrizio; IT
Priority Data
16172201.231.05.2016EP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) NOVEL COMPOUNDS
(FR) NOUVEAUX COMPOSÉS
Abstract
(EN)
This invention relates to pyrazolone derivatives having human neutrophil elastase inhibitory properties, and their use in therapy.
(FR)
L'invention concerne des dérivés de pyrazolone présentant des propriétés inhibitrices vis-à-vis de l'élastase neutrophile humaine, et leur utilisation thérapeutique.
Also published as
Latest bibliographic data on file with the International Bureau